Keychain- Phase II Randomized Trial Of Radiotherapy With Concurrent And Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy In Patients With Advanced/Intermediate-Risk P16+ Head And Neck Squamous Cell Carcinoma
Posted Date: Apr 23, 2020
- Investigator: Trisha Wise-Draper
- Specialties: Cancer, Head and Neck Cancer, Oncology
- Type of Study: Drug
The primary goal of this study is to test the hypothesis that pembrolizumab improves progression free survival (PFS) in this population compared to standard of care (RT plus cisplatin)
Criteria:
To Be Eligible: Must Have Diagnoses Of Hnscc, Adequate Organ Function, No Prior Malignancy Within 3 Years, No Prior Therapy For Study Cancer, No Hypersensitivity To Study Drugs Or Excipients, No Active Severe Co-Morbidity
Keywords:
Head And Neck Cancer, Hnscc
For More Information:
Uc Cancer Center
513-584-7698
cancer@uchealth.com